Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, G. Leslie Burnett et al.|Science|2025Cited by 31
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMallika Singh, David Wildes, Matthew Holderfield et al.|Research Square|2023Cited by 5
Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancerJoshua H. Choe, Andrew J. Aguirre, Julien Dilly et al.|Cancer Research|2025Cited by 2
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Sumit Kar et al.|Molecular Cancer Therapeutics|2025Cited by 1